Recent Updates
Recently added Catalysts
LAB Positive Sentiment Score: 70/100

Standard BioTools to Participate in Upcoming Investor Conferences

Key Takeaway: Standard BioTools Inc. will participate in two upcoming investor conferences, highlighting its commitment to advancing technology in biomedical research. David King PhD will represent the company at the Capital One Securities Spatial Biology and Proteomics Summit, while CEO Michael Egholm will speak at the TD Cowen Tools/Dx Revolution. Presentation materials will be available on the company's Investor Relations page, although webcasts will not be provided.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in significant investor conferences increases visibility.
  • Company leaders will discuss advancements in technology for biomedical research.
  • Emphasis on progressing human health breakthroughs highlights commitment to innovation.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences:
Capital One Securities 2nd Annual Spatial Biology and Proteomics Virtual Research Summit: On Tuesday, June 20, at 10:30 am ET, David King PhD, Senior Vice President, Global Research and Development, will participate in the “Pushing the Envelope of Technology with Increased Sensitivity and Higher Plex on the Horizon” Panel. Dr. King will also participate in a company presentation at 2:35 pm ET.
TD Cowen 2nd Annual Tools/Dx Revolution: On Monday, June 26, at 4:20 pm PT, Michael Egholm, President and Chief Executive Officer, will participate in the “Spatial – The Next Frontier: Clinical” Panel.
Due to the format of these events, webcasts will not be available. Presentation materials will be available on the Investor Relations page of the company’s website at Events & Presentations.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn®, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Scott R. Greenstone, CFA

Frequently Asked Questions

What is Standard BioTools Inc.'s mission?

Standard BioTools aims to unleash tools to accelerate breakthroughs in human health.

Who will participate in the Capital One Securities Summit?

David King, PhD, will participate in the Capital One Securities Summit on June 20.

When is the TD Cowen Revolution event?

The TD Cowen Tools/Dx Revolution event is on June 26 at 4:20 pm PT.

Are webcasts available for the investor conferences?

No, due to the event format, webcasts will not be available.

Where can I find presentation materials?

Presentation materials will be available on the Investor Relations page of their website.

Last updated: Jun 14, 2023